Codix’s Post

Congratulations Roambee on securing their 27th patent for the groundbreaking, "Location-based two-factor authentication delivery token"! In the realm of package deliveries, where security and reliability are paramount, Roambee addresses a critical gap. Traditionally, delivery confirmations rely solely on physical signatures, leaving room for uncertainty regarding the presence and authorization of the recipient. Roambee's latest patent revolutionizes secure package delivery by ensuring both the package and the intended recipient are physically present at the same location. This is validated through a secure, digital handshake which necessitates explicit authorization from the recipient at the same location, thereby bolstering safety, particularly for critical shipments like pharmaceuticals. Roambee continues to demonstrate its prowess in innovation and driving transformative change within the logistics industry. We are honoured to support Roambee's efforts and eagerly anticipate the far-reaching impact of their contributions. #innovation #roambeepatent #securedelivery

🚀 Exciting News from Roambee! 🌐 Roambee has been awarded its 27th patent "Location-based two-factor authentication delivery token". This patent is reimagining package delivery. In today's delivery landscape, confirming a package's delivery often relies just on a signature, missing crucial security steps. This method doesn't ensure the specific recipient is actually present or authorize the delivery personnel explicitly, especially critical for high-value items like pharmaceuticals. Recognizing this, Roambee's innovative patent introduces a game-changing solution. This system ensures that both the package and the intended recipient are in the same location, confirmed via a secure, digital handshake. It's a leap forward in securing deliveries, requiring explicit authorization from the recipient, enhancing safety for critical assets like pharmaceuticals. A significant step towards redefining secure package delivery. #Innovation #RoambeePatent #SecureDelivery

We look forward to seeing you at the FCI 56th Annual Meeting taking place on 19-23 June in Yongsan-gu Seoul. Join Gold Sponsor’s representatives, Ilia Kirilov, CODIX Group CEO, and Laurent Tabouelle, CODIX Group COO, at this premier receivable/trade finance event where industry leaders and innovators converge to drive forward the future of the industry. This year the international conference will focus on the impact of the changing economic landscape with the rise in inflation and interest rates. The agenda will address such topics as: the import factoring, how to leverage FCI’s two-member system using the edifactoring platform, the partnership between credit insurance and factoring, various Supply Chain Finance models, regional spotlights, and more. Meet CODIX top management at Booth #12 and explore together how technology can help: “Unlock Global Prosperity: Navigating the Future of Trade Finance.” Read more: https://lnkd.in/dYd-huYu FCI #CODIX #commercialfinance #tradefinance #factoring #receivables #technology #digitisation #seoul #southkorea

🎲 Block it in your calendar: Our next gambling compliance webinar, Latin America in the Limelight, is next week! Expand your horizons with Vixio's James Kilsby and Talia Samuelson as they delve into our GamblingCompliance platform so you can explore the coverage we offer across this much-discussed region. 🗓 Tuesday 14th May 🕑 2pm BST / 9am EDT By joining, you'll learn: 💡What the key policy uncertainties in Brazil are and when these are likely to be resolved 💡The different regulatory approaches across key LatAm markets to licensing, tax and certification 💡How Vixio supports regulatory and compliance teams, corporate strategy departments and more, as operators and suppliers seek to capitalise on new market opportunities ...and more! 💺 Save your seat: https://lnkd.in/e29Edrty #latinamerica #gamblingcompliance #gamblingindustry

At last month's Q2B conference, our CTO Bill Shipman got to sit down and chat with the guys from coreDevX about what we are doing with #quantumcomputing at POLARISqb. If you are interested in learning more about our case studies regarding using our #QuADD system to advance molecular research and about a lot of the companies presenting at Q2B check out this video! https://lnkd.in/gZS7rPeb

Big news in the LLM industry! Genta has achieved a significant breakthrough in reducing cold start time from 1 minute in the previous version to just 0.5 seconds. This major milestone brings cost-effective LLM deployment to everyone. We're excited to announce the release of our Private Beta API, available now for anyone interested in using our API to access Llama 3 8B. Just send me a message and I'll give you the token to try it out. But that's not all - we're also releasing Llama 3 70B, Phi 3 Mini, and Mixtral 8x7B. With this breakthrough, Genta is proud to be leading the way in cost-effective LLM deployment. We can't wait to see the impact this will have on the industry. Join us in celebrating this milestone! #Genta #LLM #API #technology #innovation

Don't gamble with your promising molecule. Make informed decisions with our Quality of Clinical Data Report (#QoCD). Whether you're on the buyer's or seller's side, a QoCD report provides comprehensive insights into the target asset, covering data quality, reliability, regulatory compliance, and study performance. Join us on June 4 for a special edition of mindsON RBQM: "M&A Efficiency: RBQM supported Clinical Due Diligence". Our experts, Anastasia Shapovalova and Sven Čohadžić will share their insights and expertise in risk-based Clinical Due Diligence. Register now and secure your spot. Take advantage of this opportunity to navigate the deal-making complexities with clarity, confidence, and speed. #ClinicalDueDiligence #RBQM #PharmaceuticalInnovations #ClinicalTrials #ClinicalResearch #NME

👉🏼 Regulatory news 𝗦𝘄𝗶𝘀𝘀𝗺𝗲𝗱𝗶𝗰 The below-amended ordinances relating to the Human Research Act (HRA, SR 810.30; https://lnkd.in/d9gyw9Qn) were approved by the Swiss Federal Council on 7 June 2024 and shall apply as of 1 November 2024, except the provisions on transparency, which enter into force on 1 March 2025. These ordinances concern human research conducted in Switzerland. ● Clinical Trials Ordinance (ClinO, SR 810.305) ● Ordinance on Clinical Trials with Medical Devices (ClinO-MD, SR 810.306) ● Human Research Ordinance (HRO, SR 810.301) ● HRA Organisation Ordinance (OrgO-HRA, SR 810.308)   Swissmedic’s annual report for 2023 (https://lnkd.in/dNRVtn8r): ● General information on Medicinal Products in Switzerland ● General information on Medical Devices in Switzerland 👉🏼 More news on #medicaldevice #regulation from us: https://lnkd.in/eHs3khty #MedDO #IvDO #RegulatoryAffairs #Switzerland #SwissMedtech #Swissmedic #Decomplix